AJCP / Meeting AbstrActs there are several other contraindications to the administration of tPA, including thrombocytopenia and coagulopathies, particularly current use of an anticoagulant. In order to address the hematologic contraindications to tPA administration, our institution offers an Emergency Stroke Panel, a STAT test including platelet count, hematocrit, fibrinogen, prothrombin time (PT) and thrombin time (TT). Although the traditional PT and TT assays are adequate for monitoring the effects of conventional oral anticoagulants, such as warfarin and dabigatran, we find they are they are not suitable for accurate measurement of the direct oral anticoagulants (DOAC). These medications, which are becomingly increasingly more common, include the direct factor Xa inhibitors rivaroxaban, edoxaban, and apixaban. For this reason, we include in our panel a modified PT (mPT) assay. This test modifies the PT assay by adding calcium chloride (CaCl 2 ) to the thromboplastin reagent to increase the dynamic range and improve sensitivity. In order to assess the utility of the mPT assay, we reviewed all orders of the Emergency Stroke panel at our two primary hospitals over the last two years, for a total of 395 patients tested with the panel. We also performed the PT, mPT, an activated partial thromboplastin time (aPTT), and an anti-Xa assay on multiple samples either from patients known to be taking DOAC or samples spiked with DOAC medications at clinically relevant concentrations. Our institution currently uses an INR of 1.7 as the cutoff for administration of tPA. For samples from patients known to be taking DOAC, as well as spiked samples, we found that 60% of rivaroxaban samples and 100% of apixaban samples yielded INR values less than 1.7. However, we found that 100% of the rivaroxaban samples and 80% of the apixaban samples could be detected using the mPT cutoffs we have established. In patients with suspected stroke, while warfarin use remained the most common reason for an elevated mPT value, the mPT was also able to detect rivaroxaban and apixaban use. Our study indicates that while factor Xa inhibitors generally do not require routine anticoagulant monitoring during clinical use, during specific emergent clinical circumstances such as stroke, the mPT can serve as a useful assay to monitor for their activity.
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A Clinical Decision Support Alert Prevents Inappropriate Repeat Laboratory Testing Ordered Within the Same Admission on Inpatients
Abraham Qavi, Jeffrey Szymanski, Ronald Jackups;Washington University, St Louis, MO Background/Objectives: Inappropriate repeat laboratory testing is a common source of waste in the medical community. Not only does it incur significant financial cost to both patients and the healthcare system, it also puts patients at risk for erroneous results. To assist clinicians in their utilization of laboratory testing, an electronic alert system was enacted at our institution that informed clinicians of inappropriate repeat testing on inpatients. We reviewed the results of this system over the past five years to assess its efficacy in altering clinical practice. Methods: An electronic query was performed of the repeat alert system at a large academic tertiary care center from September 2012 to September 2016. The alert was triggered on orders for specific assays (eg, hemoglobin A1C) on any inpatient when the same test had previously been ordered in the same admission. The ordering provider could then either cancel or continue the order after acknowledging receipt of the alert. From this data, we obtained each alert message, the corresponding laboratory assay, the time of the alert message, the ordering provider, and whether the alert message resulted in a change in medical practice, ie, cancellation of the ordered test. Results: A total of 51,367 alert values for 22 laboratory assays were identified from 19,426 unique patients. Of the alerts activated, 15,436 (30.1%) were followed by a change in clinical practice. Among the laboratory assays examined in this study, the rate at which practice was changed following an alert notification ranged from 25.1% to 63.6%. The rate at which the alert was effective in changing practice varied throughout the year, with higher effectiveness during summer months: 35.5% in July and August vs 28.9% for the remainder of the year (P < .0001). We also identified a total of 3,824 ordering providers who generated the alert values. Of these providers, 368 (9.6%) accounted for over 50% of the alerts generated. Physicians changed their practices following an alert notification more often than nurses (32.0% vs 22.1%, P < .0001). Conclusions: A duplicate laboratory test alert system is an effective tool for assisting clinicians in their decision to perform further testing. Our retrospective review revealed that the efficiency in reducing unnecessary repeat testing varied based on the type of laboratory assay, the time of year the test was ordered, and the clinician receiving the alert. These variations will allow us to more effectively target clinicians with educational opportunities to assist in clinical decision support. 
